Per Lundin is a serial entrepreneur who serves as Co-Founder & Chief Executive Officer of Evox Therapeutics Ltd. He has ~15 years of experience founding, leading and advising biotech companies developing advanced therapies. Prior to co-founding and building out Evox, he founded and led IsletOne Therapeutics, a cell therapy company developing allogeneic cell therapies for autoimmune and inflammatory diseases, which was ultimately acquired in PE-led trade sale. Over the last two decades, Per has been involved in the formation of five biotech companies developing products based on technologies ranging from cell therapies and exosomes to peptide-based drugs and non-viral delivery systems. He currently serves as board director of Breakthrough T1D International and Breakthrough T1D UK, the leading non-profit funder of research to cure, treat and prevent type 1 diabetes. He is a qualified European Patent Attorney with extensive business development and licensing experience; Per earned his Ph.D. from the Karolinska Institute, his M.S. in biotechnology engineering from the Royal Institute of Technology, and his MBA from Stockholm University School of Business.

Irina Antonijevic, M.D., Ph.D., serves as Fractional Chief Medical Officer of Evox Therapeutics. She is also Chief Medical Officer of Trace Neuroscience, a biopharmaceutical company developing genomic medicines for people living with neurodegenerative diseases.

Prior to joining Trace, Irina served as Chief Medical Officer at EveryONE Medicines, a precision medicine company targeting genetic variants causing fatal, neurodegenerative diseases. In this role, she was responsible for designing and implementing an individualized medicines platform focused on correcting uniquely rare neurogenetic mutations. She previously served as Chief Medical Officer and Head of R&D at Triplet Therapeutics, a company developing treatments for genetic conditions associated with expanded DNA nucleotide repeats. Earlier in her career, Irina held clinical and scientific roles at various pharmaceutical and biotechnology companies, including Wave Life Sciences, vasopharm GmbH, Sanofi Genzyme, Lundbeck and Schering AG.

Irina is a board-certified physician trained in psychiatry and neurology at the Max Planck Institute of Psychiatry and was an adjunct faculty member at the University of Berlin. She holds an M.D. from the Max Planck Institute of Psychiatry and a Ph.D. from the University of Edinburgh.

Dave is Head of Research at Evox Therapeutics. He has over 20 years of experience working on pioneering, multidisciplinary applied research projects. Prior to joining Evox, he led a research team that focused on extracellular vesicles as a Professor at Oxford Brookes University where he secured over £1m in grant funding and published more than 50 peer-reviewed articles. He was an active member of the International Society for Extracellular Vesicles and co-founder and first president of the UK Society for Extracellular Vesicles. His passion for exosomes brought him to Evox in 2021, where he has since supported the development of the DeliverEX platform and contributed to several pipeline projects in a matrix approach. Dave obtained his Ph.D. from the University of Cambridge where he provided the first direct in vivo demonstration that enhancers and promoters physically interact to regulate gene expression. He also spent a year at the Sanger Centre, contributing important mapping data for the Human Genome Project.

Bob is VP Finance & Operations Director at Evox Therapeutics. With over 16 years of financial experience, including a decade in the UK biotech sector, Bob is an established finance leader. He has played a pivotal role at Evox since joining in 2018, driving finance to support the company’s strategy.

Before joining Evox, Bob worked at Circassia Pharmaceuticals plc (now NIOX Group plc) where he helped scale the company post-IPO, working on multiple successful acquisitions during his tenure.

As an expert finance director, Bob has nurtured a culture of excellence within his team, empowering colleagues to excel. His financial insights have guided Evox through the complexities of biotech finance, enabling decisions that foster innovation and maintain the company’s leading position.

Bob is an ACCA certified accountant and graduated from the Reed Business School in accounting and finance.

Kerry is a strategic and commercially focused leader with significant experience in business change and transformation. Motivated by a passion to drive the culture and ethos of a company, as Head of HR at Centrica Customer Services she enabled the organisation to effectively engage with both their employees and with key audiences. With the ability to influence and build strong relationships at all levels across organisations, oversee and project manage large-scale restructuring and organisational change, Kerry is motivated to deliver through values, employee engagement and communication.

Colin Love, Ph.D., serves as Fractional Head of CMC of Evox Therapeutics and brings more than three decades of experience developing, manufacturing and launching biotechnology products.

Most recently, Colin was Chief Operating Officer and co-founder of Replimune, a biotechnology company developing oncolytic immunotherapies, where he served since 2015. Since December 2014, he has provided consultancy support to a range of life science companies, from small gene therapy start-ups to large established biotechnology companies, including Amgen. Earlier in his career, Colin was a Vice President of Clinical Operations at Amgen, where he was responsible for the two sites developing and manufacturing T-VEC, an oncolytic virus therapy approved by the FDA and EMA in 2015. Earlier in his career, Love held leadership roles at BioVex Group Inc., Celltech plc (now UCB Celltech), Medeva plc, Serono Diagnostics and Amersham International. Colin holds a Ph.D. in biochemistry from the University of Glasgow.